Get started
ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD)ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD)ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD)

ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0QNV chart


Full chart

0QNV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪10.66 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
0.0538 CHF
Net income (FY)
‪−10.56 M‬ CHF
Revenue (FY)
‪1.62 M‬ CHF
Shares float
‪58.48 M‬
Beta (1Y)
0.98

Employees


Employees (FY)
23
Change (1Y)
−1 −4.17%
Revenue / Employee (1Y)
‪70.31 K‬ CHF
Net income / Employee (1Y)
‪−458.97 K‬ CHF

About ADDEX N


Sector
Health Technology
CEO
Timothy Dyer
Headquarters
Geneva
Website
addextherapeutics.com
Founded
2002
ISIN
CH0029850754
FIGI
BBG00JYV5HQ1
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0QNV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0QNV is 0.0616 CHF — it has decreased by −3.75% in the past 24 hours. Watch ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) stocks are traded under the ticker 0QNV.
We've gathered analysts' opinions on ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) future price: according to them, 0QNV price has a max estimate of 0.21 CHF and a min estimate of 0.21 CHF. Watch 0QNV chart and read a more detailed ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) stock forecast: see what analysts think of ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) and suggest that you do with its stocks.
0QNV reached its all-time high on Apr 17, 2018 with the price of 3.4400 CHF, and its all-time low was 0.0554 CHF and was reached on Jan 23, 2024. View more price dynamics on 0QNV chart.
See other stocks reaching their highest and lowest prices.
0QNV stock is 3.90% volatile and has beta coefficient of 0.98. Track ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) stock price on the chart and check out the list of the most volatile stocks — is ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) there?
Today ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) has the market capitalization of ‪5.68 M‬, it has increased by 2.00% over the last week.
Yes, you can track ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) financials in yearly and quarterly reports right on TradingView.
ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
0QNV earnings for the last quarter are −0.02 CHF per share, whereas the estimation was −0.01 CHF resulting in a −100.00% surprise. The estimated earnings for the next quarter are −0.01 CHF per share. See more details about ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) earnings.
ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) revenue for the last quarter amounts to ‪59.00 K‬ CHF, despite the estimated figure of ‪100.00 K‬ CHF. In the next quarter, revenue is expected to reach ‪100.00 K‬ CHF.
0QNV net income for the last quarter is ‪−1.53 M‬ CHF, while the quarter before that showed ‪12.88 M‬ CHF of net income which accounts for −111.88% change. Track more ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) financial stats to get the full picture.
No, 0QNV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 23.00 employees. See our rating of the largest employees — is ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) EBITDA is ‪−4.74 M‬ CHF, and current EBITDA margin is −618.68%. See more stats in ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) financial statements.
Like other stocks, 0QNV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) stock shows the sell signal. See more of ADDEX THERAPEUTICS LIMITED CHF0.01 (REGD) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.